Liu E, Rubenstein M
Clin Pharmacol Ther. 1982 Jun;31(6):762-5. doi: 10.1038/clpt.1982.107.
Phenytoin removal was followed in a patient undergoing plasmapheresis for thrombotic thrombocytopenic purpura. It was determined that 10% of total body phenytoin was removed with each two plasma volume exchanges, which is two to four times that reported with hemodialysis or peritoneal dialysis. During each 4- to 5-hr apheresis, serum phenytoin levels fell an average of 3.2 micrograms/ml and the phenytoin clearance by plasmapheresis was 21.9 +/- 2.1 ml/min (equal to the patient's endogenous clearance of 20.8 ml/min). Adjustment in drug doses were necessary such that, at steady state, the patient required 600 mg/day phenytoin to maintain therapeutic serum levels. These data indicate that plasmapheresis can clear the body of a significant amount of phenytoin and that increased doses may be required to maintain serum phenytoin levels. The potential use of apheresis in phenytoin overdose warrants further examination.
对一名因血栓性血小板减少性紫癜接受血浆置换术的患者进行了苯妥英清除情况的跟踪。结果确定,每进行两次血浆容量置换,体内总苯妥英的10%会被清除,这是血液透析或腹膜透析所报告清除率的两到四倍。在每次4至5小时的血液分离术中,血清苯妥英水平平均下降3.2微克/毫升,血浆置换术对苯妥英的清除率为21.9±2.1毫升/分钟(等同于患者20.8毫升/分钟的内源性清除率)。需要调整药物剂量,以便在稳态时,患者每天需要600毫克苯妥英来维持治疗性血清水平。这些数据表明,血浆置换术可清除体内大量的苯妥英,可能需要增加剂量以维持血清苯妥英水平。血液分离术在苯妥英过量中的潜在应用值得进一步研究。